IVDiagnostics, Inc.

Raising $1 million to fund the commercialization of our Breast Cancer diagnostic and Covid-19 NAAT test.

Facebook Twitter LinkedIn

IVDiagnostics develops precise, real-time diagnostic tests for metastatic cancer such as breast cancer and infectious viruses like Covid-19.  Our mission is to save lives.

Our Model: IVDiagnostics sells the necessary reagents on a per-test basis. We have an 80% gross profit margin per cancer test.  With our Covid-19 test we can sell into the market as a Point of Care diagnostic for CLiA labs or as an In-home test for consumers.   Anticipated revenue is $2 million for 2022  growing to $50 million within 5 years.

The Market: According to Global Market Insights, in 2019 the market size was $109 billion USD for cancer diagnostics; $19.5 billion was spent on breast cancer diagnostic tests.

Market Growth: 1.    By 2026 the market for cancer diagnostics is expected to grow to $185 billion. The global market for Covid diagnostics is projected to rise from $84 billion USD in 2020 to $105 billion by 2027.

C
ompany Traction: IVDiagnostics is presently signing Business Development agreements with distributors that have a network of hospitals or laboratories that they service for the Covid-19 virus market.  The target markets are the U.S., Canada, Mexico, South America, Europe and Asia. 

Team Highlights: IVDiagnostics is presently signing Business Development agreements with distributors that have a network of hospitals or laboratories that they service for the Covid-19 virus market.  Our team completed a Breast Cancer clinical study and now sell its reagents as a Laboratory Directed Test.  We have also signed an exclusive marketing and commercialization agreement for a RT-LAMP NAAT molecular test that does not require the use of PCR equipment.  This permits us to bring a rapid, highly sensitive test to market at a very competitive price per test.

* Our founder is bringing the Breast Cancer diagnostic test called Velox to market because his wife suffered from metastatic cancer and a real-time monitoring tool was not available for measuring circulating tumor cells. He is passionate about helping others to save lives.

IVDiagnostics was selected by Ai Global Media as the Top producer of tools for oncologists and pathologists in the U.S.





Ready to Ask For Funding for your company?

Post a Funding Request

IVDiagnostics, Inc. is no longer seeking funding.